Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,656.00GBp
21 Jan 2019
Change (% chg)

86.00 (+1.54%)
Prev Close
5,570.00
Open
5,583.00
Day's High
5,657.00
Day's Low
5,561.00
Volume
593,502
Avg. Vol
2,055,897
52-wk High
6,432.48
52-wk Low
4,544.50

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 30.48 33.71
EPS (TTM): 2.34 -- --
ROI: 7.86 14.98 14.48
ROE: 28.47 16.31 15.99

AstraZeneca picks Baselga to lead oncology R&D in growth plan

AstraZeneca said on Monday it had hired José Baselga to head research and development in oncology, an area where the British pharmaceuticals firm is seeking to grow its business.

07 Jan 2019

AstraZeneca picks Baselga to lead oncology R&D in growth plan

AstraZeneca said on Monday it had hired José Baselga to head research and development in oncology, an area where the British pharmaceuticals firm is seeking to grow its business.

07 Jan 2019

UPDATE 2-AstraZeneca picks Baselga to lead oncology R&D in growth plan

* Creates R&D units for biopharmaceuticals and oncology (Adds comments from José Baselga, updates shares)

07 Jan 2019

AstraZeneca appoints Baselga to head R&D for oncology

Jan 7 AstraZeneca Plc has appointed José Baselga to head research and development for oncology as it looks to align the unit with its commercial operations to drive growth.

07 Jan 2019

Exclusive: Big Pharma returning to U.S. price hikes in January after pause

NEW YORK/SAN FRANCISCO Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters.

20 Dec 2018

AstraZeneca's ovarian cancer and anaemia treatments meet goals in late-stage studies

British drugmaker AstraZeneca on Thursday said its ovarian cancer and anaemia treatments met their goals in three separate late stage trials.

20 Dec 2018

AstraZeneca's ovarian cancer and anemia treatments meet goals in late-stage studies

British drugmaker AstraZeneca on Thursday said its ovarian cancer and anemia treatments met their goals in three separate late stage trials.

20 Dec 2018

AstraZeneca's ovarian cancer and anemia treatments meet goals in late-stage studies

Dec 20 British drugmaker AstraZeneca on Thursday said its ovarian cancer and anemia treatments met their goals in three separate late stage trials.

20 Dec 2018

Exclusive: Big Pharma returning to U.S. price hikes in January after pause

NEW YORK/SAN FRANCISCO Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters.

20 Dec 2018

AstraZeneca's ovarian cancer drug gets FDA nod as maintenance treatment

Dec 19 The U.S. Food and Drug Administration approved AstraZeneca Plc's cancer drug developed along with Merck & Co as a first-line maintenance treatment for adults with a form of ovarian cancer, the companies said on Wednesday.

19 Dec 2018

Earnings vs. Estimates